Genelux (GNLX) Asset Utilization Ratio (2023 - 2024)
Genelux (GNLX) recorded quarterly Asset Utilization Ratio of 0.0 in Q4 2024, up 13.95% quarter-over-quarter from 0.0 in Q3 2024, and down 96.11% on a YoY basis from 0.01 in Q1 2024.
Genelux (GNLX) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Genelux's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2024.
- In Q4 2024, Asset Utilization Ratio fell 96.11% year-over-year to 0.0; the TTM figure through Dec 2024 stood at 0.0 (down 96.11% YoY), while the FY2025 annual figure was 0.0, up 16.5% from the prior year.
- Asset Utilization Ratio was 0.0 for Q4 2024 at Genelux, up from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.01 in Q4 2023 to a low of 0.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.01 |